Editor's Corner


As I'm putting the finishing touches to this year's Fierce 15 -- to be announced at BIO on June 20 -- it's struck me how much extraordinary research work is under way in this country and around the world. It's unfortunate that for many in the public, the only news they see about the drug industry deals with some new report about a giant multinational whose biggest concern was protecting a market rather than patients. Smaller biotechs thrive and writhe on the data, and in many cases, they serve as a better model of corporate behavior than their much bigger pharma brethren.

We're in the final days leading up to our announcement of the Fierce 15 in Philadelphia. Be sure to register here if you haven't already. There promises to be quite a crowd. - John Carroll

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.